MDT (multi-disciplinary team) guidance for managing prostate cancer

References
1. Integrated Care Network. Integrated working: a guide. June, 2004. Available at: www.
integratedcarenetwork.gov.uk/docs/publications/11/13.pdf.
2. National Institute for Clinical Excellence. Guidance for commissioning cancer services. Improving
outcomes in urological cancers. The research evidence. London: NICE, 2002.
3. House of Commons Committee of Public Accounts. The NHS Cancer Plan: a progress report.
Twentieth report of session 2005−06. London: The Stationery Office, 2006.
4. Davison BJ, Parker PA, Goldenberg SL. Patients’ preferences for communicating a prostate cancer
diagnosis and participating in medical decision-making. BJU Int 2004; 93: 47−51.
5. Schroder FH, Hugosson Roobol MJ, et al. Screening and prostate cancer mortality in a randomized
European study. N Engl J Med 2009; 360: 1320−1328.
6. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate
cancer screening trial. N Engl J Med 2009; 360: 1310−1319.
7. Rosario DJ, Lane JA, Metcalfe C, et al. Contribution of a single repeat PSA test to prostate cáncer
risk assessment: experience from the ProtecT study. Eur Urol 2008; 53: 777−784.
8. Ben-Shlomo Y, Evans S, Ibrahim F, et al. The risk of prostate cancer amongst black men in the
United Kingdom: the PROCESS cohort study. Eur Urol 2008; 53: 99−105.
9. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate
cancer. Prostate 1990; 17: 337−347.
10. Negri E, Pelucchi C, Talamini R, et al. Family history of cancer and the risk of prostate cancer and
benign prostatic hyperplasia. Int J Cancer 2005; 114: 648−652.
11. Catalona WJ, Richie JP, DeKernion JB, et al. Comparison of prostate specific antigen concentration
versus prostate specific antigen density in the early detection of prostate cancer: Receiver
operating characteristic curves. J Urol 1994; 152 (6 Pt 1): 2031−2036.
12. Elgamal A-AA, Cornillie FJ, Van Poppel HP, et al. Free-to-total prostate specific antigen ratio as a
single test for detection of significant stage T1c prostate cancer. J Urol 1996; 156: 1042−1049.
13. Aus G, Becker C, Lilja H, et al. Free-to-total prostate-specific antigen ratio as a predictor of nonorgan-confined
prostate cancer (stage pT3). Scand J Urol Nephrol 2003; 37: 466−470.
14. Aus G, Becker C, Franzen S, et al. Cumulative prostate cancer risk assessment with the aid of the
free-to-total prostate specific antigen ratio. Eur Urol 2004; 45: 160−165.
15. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with
prostate cancer. J Urol 1989; 142: 1011−1017.
16. Brawer MK, Lange PH. Prostate-specific antigen in management of prostatic carcinoma. Urology
1989; 33 (5 Suppl): 11−16.
17. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localized prostate
cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990;
143: 747−752.
18. Dearnaley DP, Kirby RS, Kirk D, Malone P, Simpson RJ, Williams G. Diagnosis and management of
early prostate cancer. Report of a British Association of Urological Surgeons working party. BJU Int
1999; 83: 18−33.
19. DeAntoni EP, Crawford ED, Oesterling JE, et al. Age- and race-specific reference ranges for
prostate-specific antigen from a large community-based study. Urology 1996; 48: 234−239.
20. Xu ZQ, Hua LX, Qian LX, Wu HF. Effect of transrectal prostatic biopsy on serum prostate-specific
antigen levels. Zhonghua Nan Ke Xue 2002; 8: 341−342.
52